Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06141525
Other study ID # XJTU1AF2022LSK-427
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2024
Est. completion date March 31, 2029

Study information

Verified date April 2024
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Yang Yan
Phone +86.29.85323869
Email yangyan3@xjtu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis.


Description:

Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proved in reducing IRI in vital organs. However, the effect of RIC in patients undergoing off-pump CABG is still unclear. This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis. Patients will be randomly assigned into RIC group and control group. The primary outcome is the occurrence of the major adverse cardiovascular and cerebrovascular events (MACCE) within the 3-month follow-up. The MACCE is defined as all-cause of death, myocardial infarction, stroke and coronary revascularization surgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 648
Est. completion date March 31, 2029
Est. primary completion date December 31, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Diagnosed with coronary artery disease and require off-pump CABG surgery. - Between 18 and 75 years old; - Normal left ventricular systolic function (ejection fraction >40%) and left ventricular end-diastolic internal diameter (<60 mm) in the cardiac ultrasound tests; - No or mild heart valve and great vessel abnormalities which do not require surgical intervention; - Participants or their authorized relatives agree to participate in the clinical trial and sign the informed consent. Exclusion Criteria: - Severe tissue injuries. - Myalgia, fractures and other peripheral vascular lesions. - Bypass graft being the radial artery. - Stenosis or severe malformations of the subclavian, jugular and femoral arteries and veins. - Previous vagus nerve trunk dissection or vagus nerve block surgery. - Other surgical operations at the same time. - Patients with pre-existing severe cardiac insufficiency, acute coronary syndromes, malignant hypertension and cardiogenic shock. - Severe coagulation abnormality or severe anemia. - Severe mental disorder. - Malignant tumors. - Pregnant or lactating. - Increased risk of treatment for patients, according to investigators. - Refuse to sign the informed consent form.

Study Design


Intervention

Device:
Remote ischemic conditioning
An automatic programmed blood pressure cuff will be placed on bilateral upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg above the systolic blood pressure), with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle, and 4 cycles will be performed each time, for a total of 40 minutes.

Locations

Country Name City State
China First Affiliated Hospital of Xi'an Jiantong University Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of MACCE MACCE includes all-cause of death, myocardial infarction, stroke and coronary revascularization surgery. The data will be obtained at 3-month follow-up, according to medical records of all patients. 3-month after the enrollment.
Secondary The incidence of all-cause of death The data will be obtained at 3-month follow-up, according to medical records of all patients. 3-month after the enrollment.
Secondary The incidence of myocardial infarction The data will be obtained at 3-month follow-up, according to medical records of all patients. 3-month after the enrollment.
Secondary The incidence of stroke The data will be obtained at 3-month follow-up, according to medical records of all patients. 3-month after the enrollment.
Secondary The incidence of coronary revascularization surgery The data will be obtained at 3-month follow-up, according to medical records of all patients. 3-month after the enrollment.
Secondary The length of postoperative ICU-stay This outcome includes all days in ICU after the operation of all patients. The data will be recorded from the medical records. About 3 days after the operation.
Secondary The total length of stay in the hospital This outcome includes all days in the hospital of all patients. The data will be recorded from the medical records. About 7days after the operation.
Secondary Changes of 6-min walk test results 6-min walk test will be measured by stopwatches and metre rulers. The test assesses the overall response of all systems involved in exercise by measuring the distance the patient walks rapidly on a flat, hard surface over a period of six minutes. 3-month after the enrollment.
See also
  Status Clinical Trial Phase
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT01850082 - Randomized Endo-Vein Graft Prospective N/A
Not yet recruiting NCT04657835 - Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery. N/A
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01528514 - Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study N/A
Completed NCT01378221 - VItamin D Metabolism in SEnescent Cardiac Surgery Patients N/A
Completed NCT00848796 - Comparative Study of Two Brands of Heparin Already on the Market N/A
Not yet recruiting NCT05552586 - Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery N/A
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Completed NCT00420667 - Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery N/A
Recruiting NCT04197700 - The PRESSURE CABG Cardiac Surgery Trial N/A
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Not yet recruiting NCT06326996 - Thiamine Intervention and Coronary Artery Bypass Grafting N/A
Not yet recruiting NCT02732574 - Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery N/A
Completed NCT01182688 - Prospective Review of Procalcitonin After Cardiac Surgery N/A
Completed NCT00903604 - Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2
Completed NCT02737215 - Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Recruiting NCT05441358 - Assessment of Platelet Function in Patients Undergoing Open Heart Surgery
Recruiting NCT02400125 - China Cardiovascular Surgery Registry N/A